Gluetacs Therapeutics Announces Approval of IND Application from the FDA for GT919, an IKZF1/3 Targeted Immunomodulatory Drug Candidate

ON：2023-05-19 TAG：GLUETACS THERAPEUTICS

PRESS RELEASE

Shanghai, China – 19 May 2023

Gluetacs Therapeutics, a ShanghaiTech University-incubated company focusing on molecular glue and heterobifunctional degrader development, today announced that it has received the Investigational New Drug (IND) application approval from U.S. Food and Drug Administration (FDA) to initiate its first-in-human Phase 1 clinical trial of GT919 in patients with relapsed or refractory Multiple Myeloma. 

In China, the enrollment of GT919 study is ongoing continuously for patients with relapsed or refractory multiple myeloma. The Approval of the GT919 clinical trial application from FDA is another ground-breaking landmark in the progress of globalization of Gluetacs Therapeutics. We look forward to initiating Phase 1 study of GT919 soon in the US and the collaboration with any potential partners. “